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ABSTRACT
Background Involvement of vulnerable populations 
in research is critical to inform the generalisability of 
evidence- based medicine to all groups of the population.
Objective In this communication, we reflect on our 
previous research, and that of other authors, to identify 
and explore key ethical and methodological considerations.
Discussion Focus groups are a widely implemented 
qualitative methodology, but their use, particularly in 
vulnerable neurodegenerative disease populations, is not 
straightforward. Although the risk of harm is generally 
low in focus group research, neurodegenerative disease 
populations are particularly vulnerable to issues relating to 
comprehension and their capacity to consent. Physical and 
cognitive impairments may also affect social interactions 
among participants and therefore impact data collection 
and analyses.
Conclusion We offer a number of ethical and 
methodological recommendations to facilitate the 
processes of recruitment and data collection when 
conducting focus groups with neurodegenerative disease 
populations.
BACKGROUND
Vulnerable populations have specific health-
care needs and are therefore frequently the 
focus of research. Examples of vulnerable 
populations are patient groups with chronic 
or terminal illness, older people and young 
children, and those without capacity. Those 
diagnosed with a neurodegenerative disease 
may also be deemed as vulnerable. Neurode-
generative disease is an umbrella term used to 
describe any disease that affects the nervous 
system due to specific neuronal degeneration 
or inflammation, the main features of which 
are described in table 1.
Symptoms of these conditions can result in 
disruptions to patients’ activities and inter-
ests. Research participation is no exception 
to this, with patients and caregivers reporting 
their impairments to be a significant barrier 
to collaborating in research.1 A paternalistic 
desire to protect vulnerable populations and 
subsequently exclude them from research 
has led to subsequent ‘evidence- biased’ 
care.2 Lack of inclusion can also be viewed as 
discriminatory.3 While it can be challenging 
to involve patients with these symptoms,4 it is 
clear that meaningful, and critical, contribu-
tions to research can still be made.3
The aim of this communication is to iden-
tify the key ethical and methodological issues 
researchers face when conducting focus 
groups in a range of neurodegenerative popu-
lations. In doing so, we draw on the authors’ 
personal fieldwork experiences of conducting 
focus groups among patients with Hunting-
ton’s disease (HD) and multiple sclerosis 
(MS). A scoping review was also conducted 
in order to identify additional literature on 
conducting focus groups in a broader neuro-
degenerative population. This communica-
tion explores the challenges of conducting 
focus group research in these populations 
in terms of recruitment and data collection. 
Potential solutions are then offered.
THE CHALLENGES
Challenges of recruitment: the consent process
Capacity, comprehension and voluntari-
ness are essential components of informed 
consent.5 Informed consent is a pivotal part 
of research ethics and serves to protect the 
autonomy and right to self- determination of 
research participants. For informed consent 
to be valid, the participant must have decision- 
making capacity, which requires them to 
understand information given to them, retain 
the information long enough to process the 
decision, weigh- up the information and 
communicate their decision. Cognitive and 
behavioural changes are well documented in 
neurodegenerative disease and are associated 
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with a decline in capacity. Decision- making capacity must 
be taken into account when obtaining consent, while 
also recognising it may change over time.6 However, 
researchers should not make assumptions about a poten-
tial participant’s inability to consent purely based on 
disease status, rather they should be assumed to have 
decisional capacity unless it is established they do not 
once all practicable steps to support comprehension and 
decision making have been taken.6
In our research to develop a complex intervention to 
help slow functional decline in HD, we recruited partici-
pants from across the spectrum of HD, from prodromal 
to late- stage disease, in order to attain a diverse range 
of perspectives7 However, we were acutely aware of the 
cognitive, behavioural and emotional impairments expe-
rienced by patients with HD and their potential to impact 
on their perceived ability to provide informed consent or 
willingness to join in a group discussion. Across a range 
of neurodegenerative diseases, including HD, cognitive 
impairment affects concentration and the acquisition 
and storage of new information. This poses challenges for 
researchers who are required to obtain informed consent 
prior to any involvement in research. The 2005 Mental 
Capacity Act governs incapacitated adults’ involvement 
in research in England and Wales that is not a clinical 
trial of a medicinal product.6 This framework supports 
the inclusion of adults who are unable to provide consent 
for themselves through enabling responsible consultees 
(typically family members) to make decisions regarding 
participation on behalf of the vulnerable person. Our 
research has found that this responsibility may lead to 
exclusion of participants who would have otherwise made 
invaluable contributions.8 Focus group research remains 
a valuable method as they have been found to enable 
participants with dementia to express their needs and 
preferences, despite not having capacity as judged by clin-
ical thresholds.3
Focus group methodology is advantageous in being 
a quick and convenient way to collect data. Consent to 
participate is usually obtained immediately prior to the 
focus group and so researchers can be reassured that 
capacity is unlikely to change in the short time elapsed 
between consenting and participating in the focus group, 
although consent is always revocable. The feasibility of 
withdrawing consent during a focus group is, however, up 
for debate. Having to withdraw in a public manner that 
may disturb discussion is likely to dissuade participants 
from doing so.9
Challenges for data collection: communication
Although focus groups are rooted within a constructivist 
paradigm, with conversational flow integral to the collec-
tion of rich data, in reality, there are limitations to how far 
participants can digress from the topic of interest. In HD, 
cognition and language are highly related, and patients 
show deficits in discourse comprehension, understanding 
implicit information and making inferences. Patients also 
demonstrate decreased communicative initiative and 
significant word- finding problems. In our focus group 
fieldwork with both patients with HD and MS, we noted 
that problems in communication led to social isola-
tion.7 10 Participants with attention- related deficits related 
to cognitive decline can delay the progress of a focus 
group, potentially causing frustration for other partici-
pants and affecting the overall quality of data. Short- term 
and long- term memory deficits may lead to participants 
forgetting questions, confusing information or retrieving 
information.11 Bradyphrenia (slow processing of infor-
mation), seen in both HD and PD, hinders conversa-
tion. Dysphasia and word- finding difficulties, seen in a 
number of neurodegenerative diseases, also impact on 
communication.
A lessened ability to articulate oneself can exacerbate 
common behavioural changes such as irritability or 
aggression.11 Behavioural changes from apathy to disinhi-
bition are a core manifestation of some neurodegenera-
tive diseases and only recently has a social cognitive deficit 
been acknowledged to underlie a range of these so- called 





Autosomal dominant disorder. Core manifestations include chorea, dementia and personality changes.
Parkinson’s disease 
(PD)
Gradual onset, progressive degenerative disease. Cardinal manifestations include bradykinesia, 
tremor, rigidity or postural instability. Non- motor manifestations include autonomic dysfunction and 
neuropsychiatric features.
Multiple sclerosis (MS) Chronic, demyelinating disease of the central nervous system. Manifestations include fatigue, 
spasticity, autonomic dysfunction and visual and sensory disturbance.
Motor neuron disease 
(MND)
Degeneration of upper or lower motor neurons leads to varying patterns of signs and symptoms. 
These include atrophy, weakness, fasciculations (muscle twitch), spasticity, hyperflexia/hyporeflexia 
and hypotonia.
Alzheimer’s disease Most common form of dementia. A steady decline in cognitive functioning, with impairments in other 
areas such as executive function, language, social cognition and judgement. Accompanied by mental 
and behavioural symptoms such as depression, apathy, irritability, aggression and confusion.
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‘problem behaviours’.12 It is difficult for researchers to 
predict and control how the focus group will be expe-
rienced by individual participants.13 Even though focus 
groups are more regulated than most everyday conver-
sational encounters, no information sheet and consent 
form can detail all potential occurrences. While the risk 
of harm is low compared with other research methods, a 
duty to safeguard participants remains. Depression, apathy 
or even aggression, although rare, can cause distress and 
cause study- specific conversations to deteriorate. Some 
participants may speak out of turn or disclose views that 
distress others, potentially leaving others uncomfortable 
and reluctant to contribute.11
Challenges for data collection: motor impairment and fatigue
The visibility and unpredictability of motor symptoms 
such as hyperkinesia, instability, tremor and freezing have 
been found to be a significant barrier to participation 
in focus groups for patients with movement disorders, 
particularly those with HD and PD.1 As a result of these 
symptoms, research participants report feeling ‘exposed’ 
during social interaction.1 These concerns are shared 
by HD patients with significant chorea (abnormal invol-
untary movement) and can be exacerbated by being in 
unfamiliar environments. Researchers have encountered 
situations where participants have knocked the table or 
digital recording device, disturbing audio- recordings that 
can then further impact on the quality of transcriptions 
and data analysis.11
Choreic (involuntary) and dyskinetic (unpredictable) 
movement may also affect participants’ abilities to form 
social relationships, and therefore engage in meaningful 
discussion. Conversely, hypokinetic states (loss of move-
ment), a feature of both HD and PD, also impact on 
the ability to form relationships in social groups. Brady-
kinesia and a lack of facial expression can be as inhib-
itory as hyperkinetic movement. In MS, muscle spasms 
can be uncomfortable, unpredictable and exacerbates 
fatigue. This fatigue is typically thought to worsen as the 
day progresses.14 Similarly, progressive muscle wasting 
contributes towards significant use- dependent muscular 
fatigue in MND.
SOME ETHICAL AND METHODOLOGICAL RECOMMENDATIONS
Methods to improve the process of recruitment could 
include opportunities that allow participants to visualise 
questions that plan to be discussed prior to the focus 
group. Short ‘preinterviews’ could also allow researchers 
to assess eligibility for participation, while still regarding 
comprehension and consent as an ongoing process.15 
Making information more accessible to participants prior 
to obtaining consent has also been found to be key to 
maximising participant comprehension.16 These sugges-
tions are shared by the Mental Capacity Act’s Code of 
Practice, which recommends the use of simple language 
and imagery, such as pictures or diagrams, to improve 
the accessibility of information to those with reduced 
comprehension.6 Despite this, many researchers are still 
failing to make adequate adaptations to their information 
sheets and consent forms.17 Another approach would be 
to monitor consent throughout the focus group study. 
This form of ‘process consent’ is more sensitive to the 
issues that may arise when including vulnerable patients 
in qualitative research.17
To address bradyphrenia, memory problems or speech 
impairment, limiting the number of questions or restruc-
turing tasks within a focus group could open more time 
for discussion. In our fieldwork, including caregivers was 
deemed a necessity to facilitate the inclusion of patients 
with late- stage HD and ameliorate diminished compre-
hension and communicative abilities. We therefore 
recommend inviting relatives or staff members involved 
in participants’ care to attend alongside patient partici-
pants. In our focus groups, the presence of caregivers 
alleviated communicative and cognitive deficits, both 
in the recruitment process and during data collection; 
thus, their presence appeared to support participant 
comprehension and subsequent decision making.7 10 
Involving caregivers also demonstrates the value given to 
the carer–patient relationship and allows carers to redi-
rect the person they are supporting, clarify statements or 
even help them delve deeper into questions, although 
their input may influence patient participants’ opin-
ions. In our focus groups, healthcare professionals and 
HD association volunteers, known to some participants, 
were involved in recruitment and data collection, with 
the hope of creating a more collaborative environment.7 
However, efforts were made to prevent caregivers from 
overpowering vulnerable group members. For example, 
moderators ensured that statements made by caregivers 
were acknowledged by the appropriate patient, for verbal 
or non- verbal agreement.
As we invited people across the spectrum of disease for 
our MS and HD studies, we were aware that participants 
may become upset by seeing other patients at later disease 
stages. To minimise this discomfort, we encouraged 
participants to sit where they wished and chat to other 
participants before the focus group formally began. We 
noted that this natural group formation helped partici-
pants to become comfortable with one another, with 
group dynamics already beginning to establish.7 Thordar-
dottir also employed a strategy to create homogeneity 
within focus groups with patients with PD by grouping 
participants into mild, moderate and severe groups based 
on self- reported disease severity.1 Focus group size was 
also limited. For focus groups containing frail or vulner-
able individuals, six is the maximum recommendation,17 
and we have included a maximum of six in our focus 
groups.7 10
In order to compensate for physical and cognitive 
impairment, the structure and timings of focus groups 
should be flexible. We conducted our focus groups earlier 
in the day (but not too early) at time where physical and 
cognitive fatigue is minimal.10 If exhaustion or irritability 
arises, it may be suitable to pause the focus group and 
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resume at a later time or date. Although this may be 
time consuming, it respects participants’ autonomy and 
should contribute towards a greater quality of data. Other 
researchers working with movement disorder patients 
have conducted focus groups over a number of sessions.17
Considerations should also be made towards restricted 
physical mobility. Disabled access should always be guar-
anteed, and venues that are familiar to participants 
should be chosen wherever possible. Online focus groups 
might be helpful for some participants. Reflecting on the 
focus group environment before, during and after data 
collection also aids researchers’ reflexivity, shaping future 
methodological research considerations. We would 
recommend involving researchers who were present 
during data collection in the transcription and analysis 
processes as this counters any audio- recording issues 
encountered while also improving researcher reflexivity 
and the quality of data analysis.10
Finally, in research involving multiple human subjects, 
especially where behavioural and psychiatric changes 
may manifest themselves, consideration should also be 
given to handling safeguarding issues should they arise. 
In our research, we have found the use of vignettes to 
be a helpful strategy that allows participants to discuss 
their views without feeling pressured to disclose personal 
experiences.10 Involving clinicians and caregivers in the 
research process allows these issues to be investigated and 
managed if necessary. If distress is experienced by a partic-
ipant before or after a focus group, follow- up by health-
care professionals may also be appropriate. Researchers 
also have a duty to monitor their own welfare when 
conducting focus group on sensitive topics or with vulner-
able populations. We found that reflexivity or debriefing 
with other members of the research team preserves well- 
being and can aid data analysis.10
Table 2 summarises some of the methodological chal-
lenges and recommendations when conducting focus 
group participants in neurodegenerative disease.
CONCLUSION
Focus groups are a useful method of qualitative data 
collection, but their use within neurodegenerative popu-
lations is not without problems. Despite these issues, 
we believe that these patient populations have much to 
offer researchers and that their contributions should be 
included. This short report provides advice to researchers 
on the issues to be mindful of and offers recommenda-
tions to improve participation of this vulnerable popula-
tion in focus group research.
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Table 2 Impairments caused by neurodegenerative disease and possible implications for focus group participation
Potential impairment Possible issues Our recommendations
Impaired motor function (gross 
and fine)
Accessibility issues due to impaired 
mobility. May be unable to sign for 
written consent.
Ensure focus group venues have disabled access. 
If possible, hold in a familiar environment. Explore 
alternative options for written consent.
Involuntary movement Difficulty reading and holding items. May 
be exacerbated by stress and having to 
sit for prolonged periods. May distract 
other focus group members.
Consider homogeneity in disease stage when 
recruiting participants. Informal atmosphere 
to minimise stress. Limit focus group to six 
participants.
Physical and mental fatigue Accessibility issues. Participants may 
become fatigued and withdraw from 
discussion.
Ensure disabled access. Try to make sure venue is 
familiar. Take regular breaks or shorten focus group 
duration. Keep structure flexible and appropriate 
towards group needs. Consider the use of online 
focus groups.
Cognitive impairment Slowed thought process. Difficulty in 
storing and retrieving information.
Prompts and cues to assist retrieval. Simple 
questions. Consider involving caregivers.
Neuropsychiatric features Safeguarding issues may arise due to 
apathy, disinhibition, aggressiveness or 
suicidal ideations emerging.
Create a comfortable and informal environment. 
Consider involving caregivers. Include vignettes 
to discuss fictitious patients. Follow- up distressed 
participants.
Speech impairment, for 
example, dysphasia and 
aphasia
Impaired language skills associated with 
processing and understanding.
Allow participants adequate time to express 
themselves. Consider non- verbal forms of 
communication.
Communication Difficulty in assimilating information to 
form an appropriate response.
Simplify questions. Allow time to form a response. 
Speak in simple sentences. Limit the number of 
participants in the group.
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